Sarah Klein

Will your technology infrastructure enable the success of your #CellTherapy? In this final installment of Nuvera’s Autologous Cell Therapy (ACT) infographic series, we address the likely systems and databases that

How easy is it to order your #celltherapy? Unlike off-the-shelf products, Autologous Cell Therapies are made to order for each individual patient – successful   and seamless delivery will depend

How well have you mapped the stakeholders and functions involved with enabling the successful order, delivery, and infusion of your ACT product? Unlike traditional specialty products, even more sophisticated specialty

What Experience are you Designing for your #Celltherapy? Nuvera’s second infographic in a series of five focuses on highlighting how the experiences of patients, referring physicians, treatment centers, and the

Commercializing a CAR-T or other #Celltherapy? Nuvera is excited to share a newly developed series touching upon several commercialization issues surrounding Autologous Cell Therapies (ACTs) based upon over six years

Nuvera team members, Edward Gajewski and Jens Kulstad, hosted an informative webinar that leveraged insights gathered from over 2,000 HCPs and patients discussing where and how they learn about support